RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE …
WEB4 days ago · Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for ...
Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For …
WEB3 days ago · On Friday, Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY) for $825 million as an upfront payment and additional ...
WEBNEWS RELEASE Registered office VIA M. CIVITALI, 1 20148 MILAN, ITALY ... 4th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the ... Recordati will host a conference call today, 4th October, at 13:00 CEST (12:00 ...
Recordati buys rights to rare immune disorder drug from Sanofi …
WEB4 days ago · Oct 4 (Reuters) - Italian pharma group Recordati (RECI.MI) said on Friday it would buy from Sanofi (SASY.PA) the global rights to a drug used to treat cold agglutinin disease (CAD), a rare ...
Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo
WEB4 days ago · Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment specifically targeting cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder. The terms of the acquisition include an upfront payment of $825m from Recordati to Sanofi, plus additional milestone payments ...
In sustained rare disease push, Recordati lays out $825M upfront …
WEB3 days ago · Recordati is floating $825 million upfront—plus another $250 million in potential commercial milestones—to get its hands on the global rights to Sanofi’s rare disease biologic Enjaymo.
Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 Million
WEB4 days ago · Oct 4, 2024 6:47am. By Andrea Figueras. Recordati reached an agreement with French pharmaceutical company Sanofi to acquire the global rights to autoimmune disorder treatment Enjaymo for $825 ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE …
WEB4 days ago · Recordati will host a conference call today, 4 th October, at 13:00 CEST (12:00 p.m. GMT) to discuss the agreement to acquire Enjaymo®.The dial-in numbers for the conference call service are ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE …
WEB4 days ago · Milan, 4 th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.. Enjaymo® (sutimlimab) is a humanized monoclonal antibody indicated for the treatment of hemolysis in adults ...
Sanofi Offloads Rare Autoimmune Drug to Recordati in
WEB3 days ago · Sanofi sold Enjaymo, its humanized monoclonal antibody treatment for the rare autoimmune disorder cold agglutinin disease, to Italy’s Recordati in an agreement potentially worth more than $1 billion. Under the terms of the deal, Milan-based Recordati will pay $825 million upfront and will pledge up to $250 million in sales-based milestones.
- Some results have been removed